Start A Cure- Molecular Radiotherapy for Metastatic Prostate Cancer – A Project for You to Fund

A few days ago I wrote about Malecare’s new program addition, Start A Cure in my post “Announcing A New Research Platform – Start A Cure.” The program goal is to raise funding for cancer research by allowing each of us, as individuals, to pick the projects we want to fund and then to make [...]

Xtandi Will Hopefully be Quickly Approved in Japan

Some good news for men who are living in Japan and dealing with advanced prostate cancer. It was announced that Astellas and Medivation have submitted an application for marketing approval of Enzalutamide (Xtandi) in Japan. Their application is based on results obtained from the global Phase 3 trial (the AFFIRM trial)* and a Phase 1-2 [...]

Important – Read the Prescribing Information that Comes with Your Medications

The following is a post from Chuck Maack on the Advanced Prostate Cancer Internet support group: “It came to mind wondering how many patients and/or their caregivers prescribed Zytiga/abiraterone acetate have ever taken the important time to read all the details regarding the effects that may be experienced by patients and whether or not they [...]

Announcing A New Research Platform – Start A Cure

The news is in, and it is bad. It is as bad as many of us feared. The National Institute of Health (NIH) has announced that their across-the-board budget sequester cuts are going to equal 1.71 billion dollars. The NIH is responsible for the majority of cancer research performed in the United States. For the [...]

Hopefully A Good Re-Start from Bayer Healthcare in Mending Their Ways & Building Trust with the Prostate Cancer Community

I want to share that I am hopeful that we have made progress with Bayer Healthcare and the issues I have written about surrounding the newly approved treatment for men with castrate resistant prostate cancer, Xofigo. I have shared that they failed to support the early access trials because of what they claimed were supply [...]

Go to Top